Sanofi, RadioMedix, and Orano Med Announce Exclusive Licensing Agreement for Radioligand Therapy

Sanofi has entered an exclusive licensing agreement with RadioMedix, Inc. and Orano Med for the development of AlphaMedixTM (212Pb-DOTAMTATE), a next-generation radioligand therapy for neuroendocrine tumors (NETs). The collaboration aims to leverage the innovative radiopharmaceuticals developed by the US-based RadioMedix and the French biotech firm Orano Med to address unmet medical needs in cancer treatment.

AlphaMedixTM, currently in late-stage evaluation, targets unresectable or metastatic NETs. The therapy utilizes a somatostatin receptor-targeting peptide complex radiolabeled with lead-212 (212Pb), producing alpha particles for targeted cancer therapy. The project has recently received Breakthrough Therapy Designation from the FDA for gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

Sanofi will handle global commercialization, while Orano Med will manage manufacturing through its expanding global industrial platform. Under the agreement terms, RadioMedix and Orano Med will receive €100 million upfront and up to €220 million in sales milestones, plus tiered royalties. The agreement remains subject to regulatory approvals.